- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06163547
Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM) (STORMM)
Middle Meningeal Artery (MMA) Embolization for cSDH: Rationale and Design for the STOp Recurrence of MMA Bleeding (STORMM) Randomized-Control Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Evidence to support the benefit of MMA embolization remains limited and the risk-benefit balance remains unclear. Case series have shown that recurrence rates with embolization are much lower, and that embolization is generally very safe. Risks associated with neurointerventional procedures will be directly discussed with patients or their caretakers as part of the conventional consenting procedure. Risks include access site hematoma, radiation exposure, vascular injury, brain ischemia, death (theoretic and extremely unlikely) and typical risks associated with general or local anaesthesia. The potential efficacy of MMA embolization as a treatment therefore requires higher level evidence in the form of randomized control trials.
The benefit of the embolization is a substantial reduction in recurrence of cSDH, which has been reported to be as high 1 in 3-4 patients. Recurrence of cSDH can lead to additional surgery and complications.
First objective: Evaluate the recurrence rates of cSDH after combined surgical and MMA embolization treatments (Arm 2) versus surgery alone (Arms 1).
Second objective: The second objective is to evaluate the stability and regression of cSDH after for all the Arms of the study at follow-up.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Aria Nouri
- Phone Number: +41795530958
- Email: aria.nouri@hcuge.ch
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18-100
- Consent possible
- cSDH located at the convexities
- Patients with symptomatic cSDH
- Patients with asymptomatic large chronic/subacute hematoma after 6 weeks of failed conservative treatment
Exclusion Criteria:
- Consent not possible
- Pregnancy
- Prisoner
- Angiography contraindication
- Patient for whom follow-up is problematic (e.g. distant residency, homeless …)
- Previous surgery for cSDH
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Arm 1 - Surgery - No embolization (control)
Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1).
Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
|
|
Experimental: Arm 2 - Surgery - MMA embolisation
Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1).
Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
|
Middle meningeal artery embolization
|
Active Comparator: Arm 3 - No surgery - Embolization accepted
Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only.
Embolization accepted : Arm 3.
|
Middle meningeal artery embolization
|
No Intervention: Arm 4 - No surgery - Embolization not accepted
Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only.
Embolization refused : Arm 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence of cSDH - 1
Time Frame: 6-months
|
Surgical reoperation
|
6-months
|
Recurrence of cSDH - 2
Time Frame: 6-months
|
Neurological deterioration due to a cSDH after evacuation
|
6-months
|
Recurrence of cSDH - 3
Time Frame: 6-months
|
Post-operative hematoma volume of more than 90% of the preoperative volume at follow-up
|
6-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional clinical outcomes - 1
Time Frame: 6-months
|
Glasgow Coma Scale (Min=3; Max=15; Higher score=Best outcome)
|
6-months
|
Additional clinical outcomes - 2
Time Frame: 6-months
|
modified Ranking Scale (Min=0; Max=6; Higher score=Worse outcome)
|
6-months
|
Additional clinical outcomes - 3
Time Frame: 6-months
|
Markwalder Grading Scale (Min=0; Max=4; Higher score=Worse outcome)
|
6-months
|
Additional clinical outcomes - 4
Time Frame: 6-months
|
Glasgow Outcome Scale - Extended (Min=1; Max=8; Higher score=Best outcome)
|
6-months
|
Additional clinical outcomes - 5
Time Frame: 6-months
|
Karnofsky Performance Score (Min=20; Max=100; Higher score=Best outcome)
|
6-months
|
Additional clinical outcomes - 6
Time Frame: 6-months
|
Therapy-Disability-Neurology grading system (Min=1; Max=5; Higher score=Worse outcome)
|
6-months
|
Additional clinical outcomes - 7
Time Frame: 6-months
|
Mortality rate
|
6-months
|
Additional clinical outcomes - 8
Time Frame: 6-months
|
Re-hospitalisation for all causes
|
6-months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aria Nouri, University Hospital, Geneva
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Disease Attributes
- Hemorrhage
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Chronic Disease
- Hematoma
- Hematoma, Subdural
- Hematoma, Subdural, Chronic
Other Study ID Numbers
- 2023-00848
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Subdural Hematomas
-
Rennes University HospitalCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingChronic Subdural HematomasNetherlands
-
Ataturk Training and Research HospitalCompletedSubdural Hematoma, ChronicTurkey
-
Ospedale Policlinico San MartinoNot yet recruitingEndovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild SymptomsSubdural Hematoma, Chronic
-
University Hospital, MontpellierHospices Civils de Lyon; Centre Hospitalier Universitaire de Nice; University... and other collaboratorsTerminatedChronic Intracranial Subdural HematomaFrance
-
Balt USAAXIOM Real Time Metrics; Embo-Flüssigkeiten A.G.; Balt ExtrusionActive, not recruitingSubdural Hematoma, ChronicUnited States, France, Germany, Spain
-
Chinese University of Hong KongWithdrawnChronic Subdural Hematoma | Subdural HematomaChina
-
The University of Texas Medical Branch, GalvestonNational Institute of Neurological Disorders and Stroke (NINDS)Not yet recruitingChronic Subdural HematomaUnited States
-
Kwong Wah HospitalUnknownChronic Subdural Hematoma | Subdural DrainChina
-
Cairo UniversityCompletedMonitored Anaesthesia Care | Loco-regional Chronic Subdural Hematoma EvacuationEgypt
Clinical Trials on MMA embolization
-
Assistance Publique - Hôpitaux de ParisRecruitingChronic Subdural Hematoma | at Risk of Post-operative Recurrence | Burr-hole SurgeryFrance
-
Weill Medical College of Cornell UniversityCompletedChronic Subdural HematomaUnited States
-
Mashhad University of Medical SciencesRecruitingChronic Subdural HematomaIran, Islamic Republic of
-
Changhai HospitalNot yet recruitingTraumatic Brain Injury | EpiDural HematomaChina
-
Unfallkrankenhaus BerlinRecruitingHematoma, Subdural, ChronicGermany
-
University Hospital, BrestRecruitingChronic Subdural HematomaFrance, Martinique
-
Washington University School of MedicineRecruitingChronic Subdural HematomaUnited States
-
Angiodynamics, Inc.CompletedPulmonary Embolism | Acute Pulmonary EmbolismUnited States
-
Erasmus Medical CenterWilliam Cook Europe; Stichting CoolsingelCompletedOsteoarthritis, KneeNetherlands
-
Rigshospitalet, DenmarkCompleted